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Abstract
Background: IFN-α has been used to treat patients with chronic active hepatitis B (CAHB). Recent studies have
implicated the IL-23/Th-17 pathway in the pathogenesis of CAHB. In this study, we investigated whether IFN-α
could affect this pathway.
Methods: Peripheral blood mononuclear cells (PBMCs) obtained from patients with active CAHB (n = 61) and
controls (n = 32) were cultured with or without IFN-α, and the levels of IL-17 and IL-10 in the supernatants were
determined by ELISA, while the frequency of IL-17-expressing cells was measured by FACS. Similar experiments
were also conducted with isolated CD4+ T cells from controls. Furthermore, an experiment using an anti-IL-10
antibody was performed to examine the underlying mechanisms of action of IFN-α.
Results: Both the levels of IL-17 and the frequency of IL-17-expressing cells were significantly higher in the PBMCs
from CAHB patients than in the controls. IFN-α significantly decreased IL-17 production and the frequency of IL-17-
expressing cells in PBMCs from both patients and controls. On the other hand, IFN-α increased IL-10 production by
PBMCs from patients and controls. Anti-IL-10 antibody was able to neutralize the inhibitory effect of IFN-α on IL-17
production by PBMCs.
Conclusions: In vitro experiments showed that IFN-α could inhibit IL-17 expression and increase IL-10 production
by PBMCs and CD4+ T cells. The inhibitory role of IFN-α on IL-17 production was partly mediated by IL-10.
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Background
Hepatitis B virus (HBV) infection, the major cause of
chronic liver injury and inflammation, can lead to liver
fibrosis, cirrhosis and hepatocellular carcinoma [1,2].
IFN-α has been used for the treatment of HBV infection-
associated complications with promising results. The
mechanisms whereby IFN-α exerts its immunomodula-
tory effects in HBV-infected patients are, however, not
completely understood.
It was suggested that the IL-23/Th-17 pathway is im-
plicated in the pathogenesis of the immune response to
promote liver damage [3,4], and that the effective treat-
ment of CAHB patients with IFN-α might be mediated
via this pathway. Recent studies have shown that Type I
IFNs, including IFN-α, could inhibit IL-17 production by
peripheral blood mononuclear cells (PBMCs) [5], and
Type I IFNs were able to stimulate IL-10 production
by activated CD4+ T cells [6]. IL-10 is a cytokine of
T-regulatory Type 1 cells that can inhibit the production
of IFN-γ [7] and antigen presentation [8]. It has also
been reported that IL-10 can restrain the pathogenic role
of Th17 cells [9]. However, it is not yet known whether
IFN-α can inhibit IL-17 in CAHB, and, if so, whether it
inhibits IL-17 production directly or indirectly (for in-
stance, through the regulation of IL-10 expression). This
study was designed to investigate whether IFN-α could
inhibit IL-17 production by PBMCs in CAHB patients
and to elucidate the mechanism that is involved in this
process. Our results showed that IFN-α could signifi-
cantly inhibit IL-17 production in association with
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increased IL-10 production by PBMCs from both CAHB
patients and controls. Furthermore, similar findings were
confirmed using isolated CD4+ T cells from controls.
Interestingly, we found that the inhibitory role of IFN-α
on IL-17 production was partially mediated by IL-10.
Methods
Study population
Sixty-one inpatients with CAHB were enrolled in the
study (38 men and 23 women with an average age of
38.7 years). The diagnostic and treatment criteria were
based on the clinical practice guidelines of the “European
Association for the Study of the Liver” [10], and the
Asian-Pacific consensus statement on the management of
chronic hepatitisB: a 2012 update [11]. For all patients,
there was no evidence of metastatic or autoimmune liver
disease. The inclusion criteria were: serum HBsAg positive
for at least 6 months, alanine aminotransferase (ALT) >2
times of the normal level (< 72 IU), and Log HBV
DNA >5, but no evidence for HCC, or concomitant of
HCV, HDV, HIV infection and autoimmune liver disease.
The excluded criteria were: exposure to nucleos(t)ide
analog(s), acute hepatitis A, B, HCV, HDV, or HIV
co-infection, and drug-induced acute hepatitis, existence
of renal failure, hepatic decompensation or psychiatric dis-
orders, and central nervous system diseases, such as epilepsy,
bone marrow or organ transplants, or immunosuppressive,
nephrotoxic, or hepatotoxic medications received within
2 months of enrollment. Thirty-two healthy individuals
(17 men and 15 women, with an average age of
33.7 years) acted as controls. Patients and controls were in-
cluded in this study between October 2012 and November
2013. They were mainly from different regions of South-
west China. Written informed consent according to the
Declaration of Helsinki was obtained from each individ-
ual, and the above protocol was approved by the Clin-
ical Research Ethics Committee of the first affiliated
hospital of Chongqing Medical University. There were no
significant differences in age and gender proportion be-
tween patients and healthy volunteers (Table 1).
Cell isolation and culture
PBMCs were isolated from heparinized blood samples by
Ficoll–Hypaque density-gradient centrifugation. Peripheral
CD4+ T cells of controls were isolated from PBMCs by hu-
man CD4 microbeads (Miltenyi Biotec, Palo Alto, CA,
USA) according to the manufacturer’s instructions. The
purity of CD4+ T cells was detected using FACS Canton II
and FACS Diva software (BD Company, Franklin Lakes,
NJ, USA) after staining with anti-human CD4 antibodies
(BD Company, USA). The result showed that the purity
was >92% in each experiment. PBMCs were cultured for
72 h with or without rhIFN-α 2a (PBL Biomedical Lab,
Piscataway, NJ, USA), anti-IL-10 (R&D Systems) at a
concentration of 1 × 106 cells/ml in combination with anti-
CD3 (5 mg/ml) and anti-CD28 anti- bodies (1 mg/ml)
(eBioscience, San Diego, CA, USA). CD4+ T cells (1 × 106
cells/ml) were cultured for 72 h with or without rhIFN-α
2a (1 mg/ml) in combination with anti-CD3 (5 mg/ml)
and anti-CD28 antibodies (1 mg/ml) (Miltenyi Biotec,
Germany). Supernatants from these cell cultures were used
for detecting the concentration of IL-17 and IL-10.
Intracellular cytokine staining
As a longer incubation period was needed to study the in-
fluence of IFN-α on the IL-17 production, we first com-
pared the result of 20-h and 6-h incubation with phorbol
myristate acetate (PMA) and ionomycin in five samples.
Our result showed that there was no significant difference
concerning both IL-17 expression and the frequency of live
PBMCs between 20-h and 6-h incubation. Therefore, a 20-h
incubation was used in the following experiments. Briefly,
PBMCs from patients and controls were cultured with or
without rhIFN-α 2a (PBL Biomedical Lab, Piscataway, NJ,
USA), at a concentration of 2 × 106 cells/ml in combination
with 20 ng/ml PMA and 1 μg/ml ionomycin (Sigma, Saint
Louis, MO, USA), for 20 h and then blocked with 10 μg/ml
brefeldin A (Sigma, St Louis, MO, USA) for 4 h. The cul-
tured cells were stained with anti-CD3, anti-CD4 antibodies
(BD Company, USA), washed, fixed, permeabilized, and sub-
sequently stained with anti-IL-17A (BD Company, USA) or
appropriate isotypes (eBioscience, San Diego, CA). FACS
analysis was performed using FACS Canton II and FACS
Diva software (BD Company, USA) to determine the
in vitro effect of IFN-α on the expression of IL-17.
ELISA
Peripheral blood samples of patients and normal con-
trols were collected and placed in tubes free of pyrogen
and endotoxin. After centrifugation at a speed of
1000 × g for 15 min, serum samples were harvested and
Table 1 Demographic and clinical characteristics of the
subjects enrolled in the study
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stored at −70°C until use. The concentration of IL-17
and IL-10 in the supernatants of cultured PBMCs and
CD4+ T cells was measured using the human Duoset
ELISA development kit (R&D systems), which has a de-
tection limit of 15 and 31 pg/ml, respectively.
Statistical analysis
Paired-sample t-test was applied for within group com-
parison and one-way ANOVA was applied for between
group comparison using SPSS10.0 software (SPSS Inc.,
Chicago, IL, USA). Data are expressed as mean ± SEM.
p < 0.05 was considered as statistically significant.
Results
Concentration of IL-17 in the supernatants is higher in the
cultured PBMCs from CAHB patients than in the controls and
in both addition of rhIFN-α decreases IL-17 production.
ELISA was performed to determine IL-17 in the superna-
tants of stimulated PBMCs from patients and controls.
Stimulation of PBMCs with anti-CD3 and anti-CD28 anti-
bodies resulted in significant production of IL-17 (p < 0.001).
IL-17 levels in the cell culture supernatants of PBMCs from
CAHB patients were significantly higher than those obtained
from controls (p < 0.037). Addition of rhIFN-α 2a to this cell
culture model revealed a significantly decreased IL-17 pro-
duction both in CAHB patients and controls (Figure 1).
The frequency of IL-17-expressing CD4+ T cells is
significantly increased in CAHB patients and addition of
rhIFN-α 2a decreases the frequency of IL-17 expressing
cells from both patients and controls
We further analyzed the frequency of IL-17- expressing
T cells in CAHB patients (n = 61) and controls (n = 32)
using FACS analysis. We found that both CD4+ and
CD4-T cells expressed IL-17, but since the frequencies
of IL-17-expressing CD4-T cells were extremely low in
CAHB patients, we only investigated the CD4+ T cells.
We found that frequency of IL-17-expressing CD4+ T cells
was significantly increased in CAHB patients compared to
healthy controls (p < 0.001). Addition of rhIFN-α 2a could
decrease the frequencies of IL-17-expressing T cells in
CAHB patients and in controls (p < 0.001) (Figure 2).
rhIFN-α 2a increases IL-10 production by PBMCs from
CAHB patients and controls
ELISA was also performed to determine the levels of IL-
10 in the supernatants of stimulated PBMCs from patients
and controls. IL-10 levels in the cell culture supernatants
of PBMCs from CAHB patients were significantly higher
than those obtained from controls (p < 0.001). Addition of
rhIFN-α 2a to this cell culture model revealed a signifi-
cant increase of IL-10 production (p < 0.001) (Figure 3).
rhIFN-α 2a inhibits IL-17 production, but increases IL-10
production by isolated CD4+ T cells from healthy controls
Experiments using isolated CD4+ T cells from healthy con-
trols showed that rhIFN-α 2a also significantly inhibited
IL-17 production (p < 0.001) and promoted IL-10 produc-
tion (p < 0.001) (Figure 4). IL-17 and IL-10 levels were
much higher in experiments using isolated CD4+ T cells
from healthy individuals as compared with those in
PBMCs.
Anti-IL-10 antibody partially neutralizes the inhibitory
effect of rhIFN-α 2a on IL-17 production by PBMCs from
CAHB patients
A significant decrease of IL17 production by PBMCs
(p < 0.001) (Figure 1) was observed in the presence of
Figure 1 The inhibitory effect of rhIFN-α 2a on IL-17 production from PBMCs from CAHB patients (n = 61) and healthy controls (n = 32).
PBMCs from CAHB patients (n = 61) and healthy controls (n = 32) were cultured with or without rhIFN-α 2a at a concentration of 1 × 106 cells/ml
in combination with anti-CD3 (5 mg/ml) and anti-CD28 anti- bodies (1 mg/ml) for 72 h. IL-17 production in the supernatant of cultured PBMCs
was measured by ELISA. Columns represent meanvalues (mean + SEM).
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IFN-α, which was associated with an elevated IL-10 level
(p < 0.001) (Figure 3). To investigate the role of IL-10, we
incubated PBMCs in the presence of IFN-α and an anti-
body against IL-10. In the presence of this antibody
against IL-10, the inhibitory effect of rhIFN-α 2a on IL-17
production was partially blocked (p = 0.022) (Figure 5).
Discussion
In the present study, IL-17 levels in the cell culture su-
pernatants of PBMCs from CAHB patients were signifi-
cantly higher than those obtained from controls. Earlier
studies showed that the level of IL-17 was elevated in
CHB patients with high ALT level and suggested that
IL-17 is associated with the active intrahepatic inflam-
mation in CHB patients.
In recent studies of patients with autoimmune hepa-
titis [12] and hepatitis B [3], the degree of hepatic in-
flammation was directly correlated with Th17 cell
infiltration. In our study, the frequency of peripheral
Th17 cells in CAHB patients was found to be signifi-
cantly higher than that of normal controls. The fre-
quency of Th17 cells in the PBMC population was
examined after stimulation with PMA and ionomycin,
which are pharmacological T cell-activating agents that
mimic signals generated by the T cell receptor (TCR)
complex. However, this combinatory stimulation did not
replicate the physiological conditions by which T cells
are stimulated in vivo.
Our results are also consistent with those reported
earlier in CAHB patients. Th17 cells were found to be
highly enriched in the peripheral blood and liver, and ex-
hibited a significant potential to exacerbate liver damage
during HBV infection [3]. The frequency of peripheral
Th17 cells also correlated with ALT, suggesting a poten-
tial role for Th17 cells in the immune activation of chronic
HBV infection [13]. Recently, it was reported that the
Figure 2 Detection the Frequencies of IL-17 expressing CD4+ T cells in PBMCs from CAHB patients (n = 61) and healthy controls
(n = 32) cultured with or without rhIFN-α 2a by intracellular cytokine staining assay and FACS analysis. (A) Data from a representative
patient. Numbers indicate percentages of positive cells in that quadrant. (B) Quantitative analysis of IL-17 -expressing CD4+ T cells. Columns
represent mean values (mean + SEM).
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frequency of circulating Th17 cells in HBV-infected pa-
tients positively correlated with the severity of the disease
and the extent of liver injury. Therefore, it has been hypoth-
esized that Th17 cells might contribute to HBV disease
progression and development of liver injury [4,14].
IL-10 is an anti-inflammatory cytokine involved in the
down-regulation of the immune response. Research has
indicated that induction of IL-10 can limit proinflamma-
tory Th17 responses in HBV infected patients [15]. The
strong correlation between HBV load and the regulatory
T cell (Treg)/Th17 ratio in CAHB indicates that the im-
balance of these two cell types might contribute to HBV
persistence. Th17-mediated inflammatory diseases [16]
strongly support the notion that Th17 cells play a proin-
flammatory role in the pathogenesis of hepatitis B and
HBV infection-related injury.
The IFNs are a family of proteins with an important
role in protection against viral infections, tumor growth,
inflammation and angiogenesis [17]. The IFNs are di-
vided into three classes whereby the first two are most
important from an immunological point of view. In
humans, the main Type I IFNs consist of IFN-α (with 13
subtypes) and IFN-β (1 subtype). IFN-α is produced in
large amounts by plasmacytoid dendritic cells, whereas
IFN-β is mainly produced by fibroblasts.
IFN-α has been successfully used for the treatment of
hepatitis [18] and we wondered if IFN-α has any effects
on IL-17 and IL-10. In this study, we found that IFN-α
2a could inhibit IL-17 expression and increased IL-10
production by PBMCs from CAHB patients and con-
trols. Further experiments using isolated CD4+ T cells
from healthy controls showed similar results.
In our CAHB patients, we observed a stronger induc-
tion of IL-10 as compared with controls following incu-
bation of PBMCs with IFN-α. This result seems to
suggest that a latent negative regulatory mechanism
Figure 3 rhIFN-α 2a increase the production of IL-10 from PBMCs from CAHB patients (n = 61) and healthy controls (n = 32). PBMCs
from CAHB patients (n = 61) and healthy controls (n = 32) were cultured with or without rhIFN-α 2a at a concentration of 1×106 cells/ml in
combination with anti-CD3 (5 mg/ml) and anti-CD28 anti- bodies (1 mg/ml) for 72 h. IL-10 production in the supernatant of cultured PBMCs
was measured by ELISA. Columns represent meanvalues (mean + SEM).
Figure 4 The Expression of IL-17 and IL-10 in by CD4+ T cells from healthy controls (n =32) cultured with or without rhIFN-α 2a. CD4+
T cells from healthy controls (n = 32) were cultured with or without rhIFN-α 2a at a concentration of 1x106 cells/ml in combination with anti-CD3
(5 mg/ml) and anti-CD28 anti- bodies (1 mg/ml) for 72 h. IL-10 production in the supernatant of cultured PBMCs was measured by ELISA. Columns
represent meanvalues (mean + SEM).
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already exists in these patients but that it is not triggered
and is insufficient to suppress the overwhelming ongoing
Th17 response. We also investigated whether IFN-α
could exert its effects through up-regulation of IL-10.
The results showed that IFN-α induced both PBMCs
and CD4+ T cells to produce IL-10. We then questioned
whether IFN-α could inhibit IL-17 expression through
an up-regulation of IL-10. Therefore, an experiment
using an anti-IL-10 antibody was performed to examine
underlying mechanisms of action of IFN-α. Interestingly,
we did find that the anti-IL-10 antibody blocked the in-
hibition of IL-17 production promoted by IFN-α. These
results suggest that the function of IFN-α is at least par-
tially mediated by IL-10.
Also our results concerning the mechanism of action
of IFN-α are consistent with those reported earlier in pa-
tients with other diseases. Zhang et al. [19] showed that
IFN-α inhibited the differentiation of Th17 cells and pro-
duction of IL-17 through up-regulating TLR7 expression
in dendritic cells from patients with multiple sclerosis. It
was reported that treatment with IFN-α could induce an
increased frequency of CD4+CD25high T cells in PBMCs
from MS patients [20]. However, Seya and coworkers [21]
found that IFN-α from polyI:C-stimulated dendritic cells
(DCs) inhibited the expansion of CD4+CD25+FoxP3+
Tregs. Whether a down-regulatory effect of IFN-α on IL-
17 production by T cells, as observed in CAHB, is
associated with an increased CD4+CD25+FoxP3+ Tregs
needs further studies.
We performed these experiments using PBMCs from
healthy control patients and ideally the data should also
be confirmed using cells obtained from CAHB patients.
Other cytokines such as IL-27 that are known to be in-
duced by IFN-α and that can block the differentiation of
Th precursor cells into Th17 cells may also be involved
but were not included in our study [22,23]. Our experi-
ments using isolated CD4+ T cells from healthy controls
showed levels of IL-17 and IL-10 in the culture superna-
tants much higher than in experiments with the same
number of PBMCs. The absolute number of CD4+ T
cells was much higher in such cultures and indicated
that these cells are probably the main source of IL-17
and IL-10 in this in vitro model. On the other hand, δγ
T cells have also been shown to produce IL-17 and may
play an important role. Further studies are needed to es-
tablish which T-cell subpopulations are subject to IFN-α
regulation.
Conclusions
In conclusion, our study showed that IFN-α could
down-regulate IL-17 levels in association with an up-
regulation of IL-10 in CAHB patients and healthy con-
trols. The inhibitory effect of IFN-α on IL-17 production
was partially mediated by IL-10. Further studies are
needed to establish which T-cell subpopulations are sub-
ject to IFN-α treatment.
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